Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug maker Eli Lilly has decided to make a major investment to strengthen its biotechnology capabilities.
Subscribe to our email newsletter
The current investment will ramp up the company’s R&D of multi-specific therapeutics.
Eli Lilly intends to recruit biochemist and biologists to support its R&D for multi-specific drugs that can treat diseases in many ways at once in its Indianapolis and San Diego biotechnology facilities.
Lilly Biotechnology Discovery Research vice president Tom Bumol said they can now engineer new therapies where one medicine essentially provides the benefit of two.
"This could produce real benefits for patients, healthcare professionals and payors," Bumol said.